Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website


Xencor reported $-59365000 in EBIT for its fiscal quarter ending in March of 2023.

Ebit Change
Alnylam Pharmaceuticals ALNY:US USD -149807000 38.81M
Amgen AMGN:US USD 2.1B 129M
Arrowhead Research ARWR:US USD 48.16M 90.3M
AstraZeneca AZN:LN USD 2.78B 943M
Biogen BIIB:US USD 574.4M 304.3M
Bristol-Myers Squibb BMY:US USD 3B 686M
GlaxoSmithKline GSK:LN GBP 1.92B 483M
J&J JNJ:US USD 7.12B 826.8M
Karyopharm Therapeutics KPTI:US USD -30899000 2.97M
MacroGenics MGNX:US USD -38426000 50.41M
Merck & Co MRK:US USD 4.41B 1.14B
Novartis NOVN:VX USD 3.23B 123M
Pfizer PFE:US USD 6.91B 1.1B
Regeneron Pharmaceuticals REGN:US USD 1B 174M
Roche Holding ROG:VX 8.49B 3.05B
Seattle Genetics SGEN:US USD -154513000 509K
Xencor XNCR:US USD -59365000 16.77M